Filing Flows › Chemours (CC) › Q2 2026 › vs Q1 2026
Chemours (CC) Q2 2026 vs Q1 2026 (quarter over quarter)
Chemours's revenue rose $210M (+15%) from $1.4B in Q1 2026 to $1.6B in Q2 2026. The biggest changes: All Segments +$208M (+15%); Other Non-Reportable Segment +$2.0M (+18%).
Chemours, Q2 2026: revenue $1.6B (-2% year over year), operating margin -0.1%, net loss $274M, operating cash flow $158M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.2% | -6.7% | +13.9 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| All Segments | $1.6B | $1.4B | $208M | +15% |
| Other Non-Reportable Segment | $13.0M | $11.0M | $2.0M | +18% |
| Revenue | $1.6B | $1.4B | $210M | +15% |
| Net loss | $274M | $29.0M | $245M | +845% |
| Costs & expenses | $1.9B | $1.4B | $455M | +32% |
| Operating costs | $1.6B | $1.4B | $189M | +13% |
| Income tax | $273M | $7.0M | $266M | 39× |
| Cost of revenue | $1.3B | $1.2B | $136M | +12% |
| Operating expenses | $287M | $234M | $53.0M | +23% |
| Operating cash sources | $432M | −$15.0M | $447M | — |
| Depreciation & amortization | $80.0M | $79.0M | $1.0M | +1% |
| Share-based compensation | $7.0M | $7.0M | $0 | 0% |
| Working capital & other | $345M | −$101M | $446M | — |
| Net loss absorbed | $274M | $29.0M | $245M | +845% |
| Operating cash flow | $158M | −$44.0M | $202M | — |
| Free cash flow (OCF − capex) | $114M | −$93.0M | $207M | — |
| Capital expenditures | $44.0M | $49.0M | −$5.0M | -10% |
Questions
How much did Chemours's revenue grow quarter over quarter in Q2 2026?
Chemours's revenue rose $210M (+15%) from $1.4B in Q1 2026 to $1.6B in Q2 2026.
What drove Chemours's revenue change in Q2 2026?
All Segments +$208M (+15%); Other Non-Reportable Segment +$2.0M (+18%).